Active comorbidity and aGVHD are associated with increased risk for TA-TMA among patients who received haplo-HSCT
| Factors . | Number of patients . | TA-TMA (%) . | P . |
|---|---|---|---|
| Presence of active comorbidity | .05 | ||
| Yes | 10 | 4 (60) | |
| No | 37 | 4 (10.8) | |
| Number of transplant | .05 | ||
| First transplant | 42 | 5 (11.9) | |
| >1 transplant | 5 | 3 (60) | |
| Use of TBI conditioning | .26 | ||
| Yes | 6 | 2 (33) | |
| No | 41 | 6 (14) | |
| CSA/tacrolimus/sirolimus prophylaxis | 1 | ||
| Yes | 17 | 3 (17.6) | |
| No | 30 | 5 (16) | |
| Presence of aGVHD | .06 | ||
| Yes | 27 | 7 (25.9) | |
| No | 20 | 1 (5) |
| Factors . | Number of patients . | TA-TMA (%) . | P . |
|---|---|---|---|
| Presence of active comorbidity | .05 | ||
| Yes | 10 | 4 (60) | |
| No | 37 | 4 (10.8) | |
| Number of transplant | .05 | ||
| First transplant | 42 | 5 (11.9) | |
| >1 transplant | 5 | 3 (60) | |
| Use of TBI conditioning | .26 | ||
| Yes | 6 | 2 (33) | |
| No | 41 | 6 (14) | |
| CSA/tacrolimus/sirolimus prophylaxis | 1 | ||
| Yes | 17 | 3 (17.6) | |
| No | 30 | 5 (16) | |
| Presence of aGVHD | .06 | ||
| Yes | 27 | 7 (25.9) | |
| No | 20 | 1 (5) |
Bold numbers indicate a significant change.